Drug-Receptor Interactions

G protein-coupled receptors are the largest and most pharmacologically important receptor family, accounting for roughly one-third of all approved medications. They span the cell membrane seven times and couple to intracellular G proteins that carry the signal forward. When a drug binds, the receptor changes shape and activates a G protein, which then modulates one or more second messenger systems inside the cell. The functional outcome depends on which G protein subtype is engaged: Gs proteins stimulate adenylyl cyclase, raising cyclic adenosine monophosphate levels; Gi proteins inhibit adenylyl cyclase, lowering cyclic adenosine monophosphate; and Gq proteins activate phospholipase C, generating diacylglycerol and inositol trisphosphate, which together release calcium from intracellular stores.

The onset of action through G protein-coupled receptors ranges from seconds to minutes, reflecting the time required to produce and accumulate enough second messenger to activate downstream kinases and ion channels. Clinically familiar drugs acting at this receptor family include beta-adrenergic agonists and antagonists, opioids, muscarinic agents, histamine antagonists, and dopamine agonists and antagonists used in neurological disease.

Ligand-gated ion channels, also called ionotropic receptors, are the fastest-acting receptor type. The ion channel pore and the drug-binding site are part of the same protein complex. When a drug binds, the channel opens within milliseconds, and ions flow across the membrane down their electrochemical gradients. No second messenger is required: ion flux is the signal. These receptors mediate rapid synaptic transmission throughout the nervous system.

Clinically important examples include the gamma-aminobutyric acid type A receptor, a chloride channel targeted by benzodiazepines and barbiturates; the nicotinic acetylcholine receptor at the neuromuscular junction, which is blocked by neuromuscular blocking drugs and activated by succinylcholine; and the N-methyl-D-aspartate receptor, which is blocked by ketamine. Because response occurs in milliseconds, this receptor class mediates the most rapid pharmacological effects in clinical medicine.

Enzyme-linked receptors are cell-surface proteins whose intracellular portion either contains enzymatic activity or directly recruits an enzyme when activated. The most important subclass is the receptor tyrosine kinase family, whose members respond to growth factors and hormones including insulin, epidermal growth factor, and vascular endothelial growth factor. When the ligand binds, two receptor molecules come together (dimerize), activating the intracellular kinase domains, which phosphorylate tyrosine residues on each other and on downstream signaling proteins. The resulting phosphorylation cascade regulates cell growth, metabolism, and survival.

Because enzyme-linked receptor signaling requires propagation of a phosphorylation cascade rather than direct ion flux, the onset of action is in the range of minutes to hours rather than milliseconds. The clinical relevance of this receptor class has grown substantially with the development of targeted kinase inhibitors in oncology, such as imatinib, which blocks the breakpoint cluster region-Abelson tyrosine kinase, and trastuzumab, which targets the human epidermal growth factor receptor 2.

Nuclear receptors are intracellular proteins that function as transcription factors. Because their ligands must be lipophilic enough to cross the cell membrane and reach the cytoplasm or nucleus, this receptor class is uniquely suited to lipid-soluble molecules: steroid hormones, thyroid hormone, vitamin D, and retinoic acid are all endogenous nuclear receptor ligands.

When a drug or hormone binds, the receptor-ligand complex enters the nucleus and binds to specific sequences on the genome called hormone response elements, activating or repressing transcription of target genes. The pharmacological effect depends on production of new proteins, which takes hours to days. This slow onset is clinically consequential: glucocorticoids require hours before anti-inflammatory effects are apparent, thyroid hormone replacement takes weeks to restore metabolic steady state, and the antiresorptive effects of estrogen on bone develop over months. The slow offset of these drugs is equally important, since newly synthesized proteins persist after the drug is cleared.

A full agonist is a drug that, at high enough concentrations, produces the maximum response the receptor-effector system is capable of generating. The endogenous ligand is usually a full agonist for its own receptor. Morphine is a full agonist at the mu-opioid receptor. Epinephrine is a full agonist at adrenergic receptors. The defining feature is that the dose-response curve reaches a ceiling equal to the system maximum — Emax — given sufficient receptor occupancy.

A partial agonist binds to and activates the receptor but produces a submaximal response even when every available receptor is occupied. The maximum effect a partial agonist can produce — its ceiling effect — is less than the Emax of a full agonist at the same receptor. This ceiling is intrinsic to the drug, not a consequence of insufficient dose.

Partial agonism creates a dual pharmacological behavior that depends on context. When a partial agonist is given alone, it produces a net activating effect — it is, after all, activating receptors. But when given in the presence of a full agonist (including an endogenous one), the partial agonist competes for receptor occupancy and, because each partial agonist-occupied receptor generates less signal than a full agonist-occupied receptor would, the net result is reduced effect compared to the full agonist alone. In a high-agonist environment, partial agonists behave functionally as antagonists.

Buprenorphine illustrates this clinically. As a partial agonist at the mu-opioid receptor with very high affinity, it produces analgesia and reduces opioid craving. Its ceiling effect on respiratory depression is a meaningful safety advantage over full agonist opioids. Its high affinity means it binds tightly and displaces full agonist opioids from their receptors, which is the basis for using it in opioid use disorder — but also means that administering it to a patient with full agonist opioids still occupying receptors can precipitate withdrawal, because the partial agonist displaces the full agonist and delivers less total receptor activation.

Aripiprazole, an atypical antipsychotic, is a partial agonist at dopamine D2 receptors. In brain pathways where dopamine is overactive (mesolimbic pathways, which mediate psychotic symptoms), aripiprazole competes with dopamine and produces net dopamine blockade. In pathways where dopamine tone is low (mesocortical pathways, which mediate cognition), aripiprazole provides net agonist activity. This context-dependence is what distinguishes partial agonists from simple antagonists in clinical practice.

Some receptors, particularly G protein-coupled receptors, are not completely inactive in the absence of a ligand. They have a low level of spontaneous activity — constitutive activity — that produces measurable baseline signaling. A neutral antagonist blocks access of agonists to the receptor without changing this baseline constitutive activity. An inverse agonist, by contrast, binds the receptor and actively suppresses constitutive activity below the basal level, producing an effect in the direction opposite to an agonist.

Many drugs previously classified as simple antagonists are now recognized as inverse agonists. Beta-blockers such as metoprolol and carvedilol are inverse agonists at the beta-1 adrenergic receptor: they not only block catecholamine-stimulated activation but also suppress the constitutive receptor activity that is elevated in heart failure. This may contribute to the clinical benefit of beta-blockers in chronic heart failure beyond simple sympatholysis. For the purposes of clinical pharmacology at this level, the key distinction to carry forward is that inverse agonists suppress constitutive receptor activity, while neutral antagonists do not.